Announcements Trials

Browse Landscape

Phase

Status

Completed 1 Active not recruiting 1

Sponsor Class

OTHER 1 INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

von Hippel-Lindau Disease 1 Carcinoma, Renal Cell 1

Interventions

Paclitaxel 490 Carboplatin 436 Gemcitabine 394 Docetaxel 385 Cisplatin 360 pembrolizumab 344 Bevacizumab 335 Nivolumab 261 Pemetrexed 243 Capecitabine 221 Dexamethasone 213 Fluorouracil 211 Rituximab 203 Trastuzumab 193 Cyclophosphamide 190 Oxaliplatin 160 Erlotinib Hydrochloride 147 Ipilimumab 145 atezolizumab 144 Prednisone 144 Cetuximab 142 Irinotecan 139 Leucovorin 130 Doxorubicin 130 Sorafenib 120 Lenalidomide 119 Bortezomib 118 Sunitinib 107 Everolimus 93 130-nm albumin-bound paclitaxel 92

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Completed × INDUSTRY × PT2385 × Clear all

NCT03108066 2024-09-24

MK-3795-003

Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Phase 2 Completed

4 enrolled 11 charts

Carcinoma, Renal Cell, von Hippel-Lindau Disease

Data powered by HemOnc (CC BY 4.0) Colophon ⚡